STALLERGENES-GREER
9.7.2021 10:02:12 CEST | Business Wire | Press release
Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), and Alyatec, a contract research organisation based in Strasbourg University Hospital (France), today announced that they have entered into a collaboration to advance precision medicine in AIT.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210709005081/en/
With this collaboration, Stallergenes Greer aims to strengthen its precision medicine-based approach and the management of patients with allergies by expanding its knowledge of allergy pathophysiology and endotypes, AIT mode of action and clinical validation.
This research collaboration brings together the longstanding expertise of Stallergenes Greer in AIT and Alyatec’s competencies in research and clinical services as well as its state-of-the-art technology, including a new generation environmental exposure chamber.
“We are excited about the collaboration with Alyatec which will support Stallergenes Greer’s ambition to advance the practice of allergology. With Alyatec and its team of distinguished key opinion leaders, Stallergenes Greer will continue to build on precision medicine and personalised healthcare to significantly improve patient disease outcomes ”, declared Amer Jaber, Executive VP Operations Europe and International and President of Stallergenes SAS.
“This collaboration is a remarkable opportunity for Alyatec to develop precision medicine in AIT. The field of allergology is the oldest form of precision medicine as patient phenotypes are directly related to specific results provided by skin tests. We are convinced that adapting immunotherapy to the phenotype of each patient, in other words finding the right immunotherapy for the right patient, is the future of AIT,” stated Professor Frédéric de Blay, Principal investigator and Medical expert of Alyatec.
ABOUT ALLERGEN IMMUNOTHERAPY
Allergies are the most prevalent and fastest growing chronic disease in the industrialised world, affecting over one billion people worldwide1 . Allergen immunotherapy is an allergy treatment designed to alter the natural course of respiratory allergies by treating the underlying cause of the disease. Allergen extracts are modifying disease by inducing tolerance in the immune system2,3 .
ABOUT STALLERGENES GREER
Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergy immunotherapy products and services. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).
ABOUT ALYATEC
Alyatec is a contract research organisation based in Strasbourg University Hospital (France) which performs clinical studies related to respiratory allergies. Thanks to its specific knowledge and medical expertise Alyatec can evaluate the effect of solutions against asthma, rhinitis and conjunctivitis caused by environmental factors such as cat allergens, pollens and house dust mites. To perform these clinical trials, Alyatec has an environmental exposure chamber which enables the assessment of the mode of action of allergy treatment solutions in an innovative and efficient way. The company provides a full range of clinical services in the area of respiratory allergies with all the benefits related to the use of Alyatec’s allergen exposure unit.
1.World Health organisation, Ambient Air Pollution: Health Impacts
2.Global Atlas of Allergy, EAACI 2014
3.Halken 2017: EAACI guidelines on allergen immunotherapy: Prevention of allergy
View source version on businesswire.com: https://www.businesswire.com/news/home/20210709005081/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
Xsolla Launches Game Biz Institute, an Editorial Platform Where Industry Practitioners Explain the Business of Games27.8.2026 17:32:00 CEST | Press release
New Platform Pairs Independent Researchers and Industry Veterans with Xsolla Experts to Unpack Direct-to-Player Commerce, Monetization, Payments, and Player Retention Xsolla, a global commerce company, today announced the launch of Game Biz Institute (GBI), an editorial platform where named industry practitioners and researchers examine the commercial layer of games: direct-to-player distribution, payments, monetization, user acquisition, and retention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827362663/en/ Graphic: Xsolla Game design has a curriculum. The business of games does not. Engines, pipelines, production, and narrative are taught at hundreds of universities, while the commercial machinery that determines whether good work becomes a durable company is still learned through expensive trial and error, usually after the decisions that mattered have already been made. GBI was built to close that gap by publishi
Star Wars Zero Company™ Now Available On PC, PlayStation 5 and XBOX Series Consoles27.8.2026 17:00:00 CEST | Press release
Bit Reactor’s Debut Title Combines Tactical Depth and Cinematic Elegance for a New Star Wars StoryWatch the Final Trailer to Witness What’s at Stake in the Galaxy Electronic Arts Inc. and Bit Reactor, in collaboration with Lucasfilm Games, announced today that Star Wars Zero Company™, a single-player turn-based tactics game set in the twilight of the Clone Wars™, is now available for PC via the EA app, Steam, and Epic Games Store, and PlayStation®5 and XBOX Series consoles. In Star Wars Zero Company, former Republic officer Hawks and Zero Company, an elite squad of unconventional professionals for hire, are recruited for an operation by Republic Intelligence. From ex-nobles to ex-cons, they now share one mission: Stop the Infinite Coil, a Separatist-aligned cult, and their leader Kundri Fathom before the deadly Shadow Plague consumes the galaxy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012810/en/ https://www.yout
Rehlko Joins Wisconsin Data Center Coalition as Newest Energy Resilience Member, Reinforcing Its Role at the Center of AI and Digital Infrastructure Growth27.8.2026 15:15:00 CEST | Press release
Global Energy Resilience Leader Reinforces Its Role at the Center of AI and Digital Infrastructure Growth Through Mission-Critical Power Expertise Rehlko, a global industrial energy resilience platform providing custom-engineered, integrated power solutions for mission-critical infrastructure worldwide, today announced it has joined the Wisconsin Data Center Coalition (WIDCC) as the organization's newest energy resilience member. The membership reflects Rehlko's commitment to advancing Wisconsin's role as a leader in responsible AI infrastructure development, built on reliable and scalable power. Rapid growth in hyperscale and enterprise data center investment is reshaping markets across the world, and Rehlko is building the power infrastructure that makes it possible. Sitting at the intersection of the structural forces driving AI infrastructure expansion, grid reliability, and accelerating electrification, Rehlko brings more than a century of engineering depth and lifecycle capabilit
GenNx360 Capital Partners Closes Fourth Flagship Fund at $865 Million27.8.2026 14:30:00 CEST | Press release
Fund IV success is the result of two decades of proven performance backing lower middle market industrial services and business services companies GenNx360 Capital Partners (“GenNx360” or “the Firm”), a New York City-based private equity firm investing in U.S. lower middle market industrial services and business services companies, today announced the successful closing of GenNx360 Capital Partners IV, L.P. (“Fund IV” or “the Fund”), with $865 million in commitments, exceeding its target. Fund IV is the largest fund raised in GenNx360’s history. Fund IV was supported by a diverse group of existing and new investors including leading pensions, asset managers, insurance companies, foundations, and family offices, reflecting conviction in the firm’s disciplined investment approach, operational value creation model, and tenured, diverse team. Fund IV will continue GenNx360’s differentiated strategy of partnering with lower middle market founders and management teams to scale essential serv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom